



(51) International Patent Classification:

A61P 31/14 (2006.01)

A61K 39/12 (2006.01)

A61K 39/215 (2006.01)

(21) International Application Number:

PCT/US2021/019662

(22) International Filing Date:

25 February 2021 (25.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/981,451	25 February 2020 (25.02.2020)	US
62/981,168	25 February 2020 (25.02.2020)	US
63/004,380	02 April 2020 (02.04.2020)	US
63/022,032	08 May 2020 (08.05.2020)	US
63/028,404	21 May 2020 (21.05.2020)	US
63/033,349	02 June 2020 (02.06.2020)	US
63/040,865	18 June 2020 (18.06.2020)	US
63/046,415	30 June 2020 (30.06.2020)	US
63/056,996	27 July 2020 (27.07.2020)	US
63/062,762	07 August 2020 (07.08.2020)	US
63/063,157	07 August 2020 (07.08.2020)	US
63/114,858	17 November 2020 (17.11.2020)	US
63/130,593	24 December 2020 (24.12.2020)	US
63/136,973	13 January 2021 (13.01.2021)	US

(71) Applicants: INOVIO PHARMACEUTICALS, INC.

[US/US]; 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 (US). **THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY** [US/US]; 3601 Spruce Street, Philadelphia, PA 19104 (US).

(72) Inventors; and

(71) Applicants: **YAN, Jian** [US/US]; 503 Sheffield Drive, Wallingford, PA 19086 (US). **BRODERICK, Kate** [US/US]; 5806 Ridgemoor Drive, San Diego, CA 92120 (US). **WEINER, David** [US/US]; 717 Beacom Lane, Merion, PA 19066 (US). **MUTHUMANI, Kar** [US/US]; 52 Ivy Lane, Cherry Hill, NJ 08002 (US). **PATEL, Ami** [CA/US]; 2642 Catharine Street, Philadelphia, PA 19146 (US).


(74) Agent: **GROTH, Felicity, E.**; Baker & Hostetler, LLP, 2929 Arch Street, Cira Centre, 12th Floor, Philadelphia, PA 19104-2891 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: VACCINES AGAINST CORONAVIRUS AND METHODS OF USE

Figure 1



(57) Abstract: Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject.



Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*